µ-opioid receptor activation at the dorsal reticular nucleus shifts diffuse noxious inhibitory controls to hyperalgesia in chronic joint pain in male rats
Copyright © 2024 American Society of Anesthesiologists. All Rights Reserved..
BACKGROUND: The dorsal reticular nucleus is a pain facilitatory area involved in the diffuse noxious inhibitory controls (DNIC), through opioidergic mechanisms that are poorly understood. We hypothesized that signaling of µ-opioid receptors is altered in this area at prolonged chronic inflammatory pain and that this accounts for the loss of DNIC occurring in this condition.
METHODS: Monoarthritis was induced in male Wistar rats (n=5-9/group) by tibiotarsal injection of complete Freund's adjuvant. We quantified the immunolabeling of µ-opioid receptors and the phosphorylated forms of µ-opioid receptors and cAMP response element-binding protein. Pharmacological manipulation of µ-opioid receptors at the dorsal reticular nucleus was assessed in DNIC, through the Randall-Selitto test.
RESULTS: At 42 days of monoarthritis, µ-opioid receptor labeling decreased at the dorsal reticular nucleus, while its phosphorylated form and the phosphorylated cAMP response element-binding protein increased. D-ALA2,N-ME-PHE4,GLY5-OL)-enkephalin acetate (DAMGO) enhanced DNIC analgesia in normal animals ([Mean ± SD]: pre-DNIC: 126.9 ± 7.0g; DNIC - DAMGO: 147.5 ± 8.0g vs. DNIC + DAMGO: 198.1 ± 19.3g, p < 0.001), whereas it produced hyperalgesia in monoarthritis (pre-DNIC: 67.8 ± 7.5g; DNIC - DAMGO: 70.6 ± 7.7g vs. DNIC + DAMGO: 32.2 ± 2.6g, p < 0.001). An ultra-low dose of naloxone, which prevents the excitatory signaling of the µ-opioid receptor, restored DNIC analgesia in monoarthritis (DNIC - Naloxone: 60.0 ± 6.1g vs. DNIC + Naloxone: 98.0 ± 13.5g, p < 0.001), compared to saline (DNIC - Saline: 62.5 ± 5.2g vs. DNIC + Saline: 64.2 ± 3.8g). When injected prior to DAMGO, it restored DNIC analgesia and decreased the phosphorylated cAMP response element-binding protein in monoarthritis.
CONCLUSIONS: The dorsal reticular nucleus is likely involved in a facilitatory pathway responsible for DNIC hyperalgesia. The shift of µ-opioid receptor signaling to excitatory in this pathway likely accounts for the loss of DNIC analgesia in monoarthritis.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
Anesthesiology - (2024) vom: 21. Feb. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Pereira-Silva, Raquel [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 21.02.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.1097/ALN.0000000000004956 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368719855 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM368719855 | ||
003 | DE-627 | ||
005 | 20240222232946.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240222s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1097/ALN.0000000000004956 |2 doi | |
028 | 5 | 2 | |a pubmed24n1302.xml |
035 | |a (DE-627)NLM368719855 | ||
035 | |a (NLM)38381969 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Pereira-Silva, Raquel |e verfasserin |4 aut | |
245 | 1 | 0 | |a µ-opioid receptor activation at the dorsal reticular nucleus shifts diffuse noxious inhibitory controls to hyperalgesia in chronic joint pain in male rats |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 21.02.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a Copyright © 2024 American Society of Anesthesiologists. All Rights Reserved. | ||
520 | |a BACKGROUND: The dorsal reticular nucleus is a pain facilitatory area involved in the diffuse noxious inhibitory controls (DNIC), through opioidergic mechanisms that are poorly understood. We hypothesized that signaling of µ-opioid receptors is altered in this area at prolonged chronic inflammatory pain and that this accounts for the loss of DNIC occurring in this condition | ||
520 | |a METHODS: Monoarthritis was induced in male Wistar rats (n=5-9/group) by tibiotarsal injection of complete Freund's adjuvant. We quantified the immunolabeling of µ-opioid receptors and the phosphorylated forms of µ-opioid receptors and cAMP response element-binding protein. Pharmacological manipulation of µ-opioid receptors at the dorsal reticular nucleus was assessed in DNIC, through the Randall-Selitto test | ||
520 | |a RESULTS: At 42 days of monoarthritis, µ-opioid receptor labeling decreased at the dorsal reticular nucleus, while its phosphorylated form and the phosphorylated cAMP response element-binding protein increased. D-ALA2,N-ME-PHE4,GLY5-OL)-enkephalin acetate (DAMGO) enhanced DNIC analgesia in normal animals ([Mean ± SD]: pre-DNIC: 126.9 ± 7.0g; DNIC - DAMGO: 147.5 ± 8.0g vs. DNIC + DAMGO: 198.1 ± 19.3g, p < 0.001), whereas it produced hyperalgesia in monoarthritis (pre-DNIC: 67.8 ± 7.5g; DNIC - DAMGO: 70.6 ± 7.7g vs. DNIC + DAMGO: 32.2 ± 2.6g, p < 0.001). An ultra-low dose of naloxone, which prevents the excitatory signaling of the µ-opioid receptor, restored DNIC analgesia in monoarthritis (DNIC - Naloxone: 60.0 ± 6.1g vs. DNIC + Naloxone: 98.0 ± 13.5g, p < 0.001), compared to saline (DNIC - Saline: 62.5 ± 5.2g vs. DNIC + Saline: 64.2 ± 3.8g). When injected prior to DAMGO, it restored DNIC analgesia and decreased the phosphorylated cAMP response element-binding protein in monoarthritis | ||
520 | |a CONCLUSIONS: The dorsal reticular nucleus is likely involved in a facilitatory pathway responsible for DNIC hyperalgesia. The shift of µ-opioid receptor signaling to excitatory in this pathway likely accounts for the loss of DNIC analgesia in monoarthritis | ||
650 | 4 | |a Journal Article | |
700 | 1 | |a Teixeira-Pinto, Armando |e verfasserin |4 aut | |
700 | 1 | |a Neto, Fani L |e verfasserin |4 aut | |
700 | 1 | |a Martins, Isabel |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Anesthesiology |d 1945 |g (2024) vom: 21. Feb. |w (DE-627)NLM00001267X |x 1528-1175 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:21 |g month:02 |
856 | 4 | 0 | |u http://dx.doi.org/10.1097/ALN.0000000000004956 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 21 |c 02 |